These clinical trial results accelerated the FDA approval of pertuzumab and established the standard of pertuzumab + trastuzumab + chemotherapy in the first-line treatment of patients with HER2-positive metastatic breast cancer and the adjuvant treatment of HER2-positive early breast cancer. Here, ERBB2 is linked to breast carcinoma.